Ovid Therapeutics Inc. 8-K

What Happened

• Ovid Therapeutics Inc. filed an 8‑K reporting that on May 29, 2026 its Board approved, effective June 15, 2026, an increase in board size and the appointment of Anna Greka, M.D., Ph.D., as a Class III director. Her term expires at the Company’s 2029 annual meeting of stockholders.
• Dr. Greka, age 50, is a Professor of Medicine at Harvard Medical School and Mass General Brigham and holds multiple leadership roles at the Broad Institute. She has served as a venture advisor and founder/advisor to several biotech companies.

Key Details

• Effective date of appointment: June 15, 2026.
• Board size after appointment: seven directors.
• Term: Class III director, term expiring at the 2029 annual meeting.
• Committee assignments: member of the Compensation Committee and Science and Technology Committee (effective June 15, 2026).
• Compensation: Dr. Greka will be paid under the Company’s standard non‑employee director compensation policy (see proxy filed April 27, 2026).
• Indemnification: Dr. Greka entered the Company’s standard form of indemnification agreement (may cover certain expenses, attorneys’ fees, judgments, fines, settlements related to service as a director).
• No related-party arrangements or transactions requiring disclosure under Item 404(a) of Regulation S‑K; no other understandings regarding her selection.

Why It Matters

• The appointment increases the board to seven members and adds a director with deep academic, research and biotech experience, which may strengthen the Company’s scientific and governance expertise.
• Compensation and indemnification follow the Company’s standard policies, indicating this is a routine board appointment from a corporate governance and cost perspective.